Astra Zeneca

Ben Challis is VP and Head of Translational Science & Experimental Medicine in Early CVRM at AstraZeneca, a role in which he oversees the target validation, biomarker and precision medicine strategies for drug projects in the CVRM portfolio.

He is currently an Honorary Consultant in Endocrinology at Addenbrooke’s Hospital in Cambridge, and Director of Studies for Clinical Medicine at St Edmund’s college. His current research interests include metabolic disease & genetics and inherited tumour syndromes.

A discovery innovations leader and mentor across target selection, pipeline delivery to first time in human (FiH) and the related technology stack. 22 years experience (Cambridge Antibody Technology, MedImmune & AstraZeneca) as a biologics and antibody engineer, team leader, pipeline project leader and mentor of leaders. A very experienced and successful multidisciplinary team leader with an exemplary high performance track record.